Biocon has informed that the US Food and Drug Administration (USFDA) concluded a GMP inspection of our API facility (Site 6), located at Visakhapatnam, Andhra Pradesh, on 14 June 2024. Three observations were cited at the end of the Inspection, which they will be addressing within the stipulated time. Biocon stands committed to Quality, Safety & Efficacy of the products manufactured. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.